GSK plc
linerixibat
cholestatic pruritus in primary biliary cholangitis (PBC)
Resolved
105days ago
Approval decision · Mar 24, 2026
What's at stake
A final FDA approval decision on linerixibat for cholestatic pruritus in primary biliary cholangitis (PBC) is expected Mar 24, 2026.
Primary source
· SEC 6-K
verified 13h ago
“Financial considerations Under the terms of the agreement, GSK will receive an upfront payment of $300 million, plus $100 million upon US FDA approval (expected prior to transaction closing, based on current PDUFA target approval date of 24”